关键信息
-
基因名
IL-1R2
- 应用
-
别名
CD121b; CD121-B; IL1-R2; IL1RB; Interleukin-1 Receptor Beta; CD121 Antigen-like Family Member B
-
种属
Mouse
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P27931
-
表达区间
Phe14~Pro247
-
分子量
30kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
Interleukin-1 receptor type 2 (IL-1R2) is a crucial component of the interleukin-1 (IL-1) signaling pathway, which plays a significant role in the immune response and inflammation. As a decoy receptor, IL-1R2 binds to IL-1α and IL-1β, preventing their interaction with the signal-transducing receptor IL-1R1, thereby inhibiting pro-inflammatory signaling. This unique functionality positions IL-1R2 as a potential therapeutic target for various inflammatory and autoimmune diseases, such as rheumatoid arthritis, sepsis, and other chronic inflammatory conditions. Research on recombinant IL-1R2 proteins has gained traction, focusing on their role as anti-inflammatory agents. Studies have demonstrated that the recombinant protein can effectively reduce inflammation by blocking IL-1 mediated signaling pathways, leading to decreased cytokine production and immune cell activation. Additionally, understanding the structural and functional characteristics of IL-1R2 has paved the way for the development of novel therapeutic strategies, including the design of IL-1R2 fusion proteins or monoclonal antibodies that can enhance its efficacy. The potential application of IL-1R2 in clinical settings is significant as it opens new avenues for treatment, highlighting the importance of ongoing research to fully elucidate its mechanisms, optimize rescue strategies, and assess its effectiveness in human disease models. Consequently, recombinant IL-1R2 proteins not only present a promising landscape in immunological research but also hold transformative potential in therapeutic interventions aimed at managing acute and chronic inflammatory disorders.
